The Crown Has Changed Hands: October 30, 2025 Marks a Historic Pharma Shift
For nearly a decade, Merck's Keytruda dominated as the world's best-selling drug. That era just ended.
THE NUMBERS:
📊 Q3 2025 Sales:
- Mounjaro + Zepbound (Lilly): $10.1B (+109% YoY) — NEW #1
- Keytruda (Merck): $8.1B (+10% YoY) — #2
- Ozempic + Wegovy (Novo): $7.9B (+10% YoY) — #3
Tirzepatide is now tracking toward $32B+ annually—a $400M+ lead over #2.
BUT HERE'S THE REAL STORY:
While semaglutide briefly led in H1 2025 ($16.7B), it couldn't sustain. Why? Five critical factors:
1. Clinical Superiority (47% Better Weight Loss)
Tirzepatide's dual GIP/GLP-1 mechanism delivers 20.2% weight loss V/S semaglutide's 13.7%. Patients see results faster → loyalty is permanent.
2. Manufacturing Foresight ($50B Investment)
Lilly invested $50B+ in manufacturing capacity (2020+). Novo scrambled during 2023-2024 FDA shortages. Supply reliability = market share capture. By normalization, Lilly owned mindshare.
3. Compounding Devastation (1M+ Lost Patients)
Semaglutide compounding shipments DOWN 90% (June 2024-2025). Tirzepatide? DOWN only 34%. Over 75% of compounders targeted semaglutide. Novo's CEO: "Mass compounding continues affecting Wegovy prescription rates." These 1M+ patients never returned to branded Novo—they switched to tirzepatide or stayed compounded. Permanent market loss.
4. Market Access Innovation (LillyDirect)
Lilly bypassed traditional PBM distribution:
- Uninsured: $349/month for Zepbound
- Insured: $25 copay
- Result: 35% of prescriptions are CASH-PAY (unprecedented for pharma)
Plus: Geographic dominance (India playbook—Mounjaro launched 3 months before Wegovy, became India's #2 brand in 7 months).
5. Patent Runway (15+ Years vs 1-3 Years)
- Keytruda expires 2028 (19% revenue decline predicted)
- Semaglutide expires 2026-2027 (biosimilars incoming NOW)
- Tirzepatide expires ~2040+ (12+ year runway to optimize, innovate, maximize)
THE MARKET CONTEXT:
GLP-1 market expanding explosively:
- 2025: $66.5B
- 2034: $879.9B (33% CAGR)
- Tirzepatide projected 44% share by 2035 vs semaglutide's 37%
WHAT'S NEXT:
Threats emerging (Amgen's MariTide, Novo's oral, Pfizer's pipeline), but Lilly's defensive posture is strong:
- Oral GLP-1 (orforglipron) filing by end of 2025
- Triple agonists in pipeline
THE REAL LESSON:
This wasn't luck. It was Execution > Innovation.
Novo had first-mover advantage. Merck built an empire. But Lilly executed a masterclass in manufacturing foresight, supply chain superiority, market access innovation, and patent strategy.
In 2025, execution precision is as valuable as breakthrough innovation.
The pharmaceutical crown pivot isn't just a sales ranking shift. It signals a fundamental industry restructuring: from innovation-driven to execution-driven competition. Obesity & metabolic disease aren't replacing oncology—they're reshaping how pharma operates.
The game changed. Not just the crown
hashtag#Mounjaro hashtag#Keytruda hashtag#GLP1